| Literature DB >> 35118221 |
Eric I Benchimol1,2,3,4,5, Waqqas Afif6, Sophie Plamondon7,8, Dennis Newhook4, Stuart G Nicholls9, Dominique Lévesque10.
Abstract
BACKGROUND: The transfer of information is a key aspect of the transition of adolescent patients with inflammatory bowel disease (IBD) from pediatric to adult care. This is typically accomplished through the use of a consultation letter with a medical summary of the patient being transferred. To improve the quality and completeness of information included in a transfer letter, we developed a standardized medical summary template by integrating the feedback of adult and pediatric health care providers.Entities:
Keywords: Crohn’s disease; Health services research; Inflammatory bowel disease; Pediatrics; Qualitative research; Transition from pediatric to adult care; Ulcerative colitis
Year: 2021 PMID: 35118221 PMCID: PMC8806045 DOI: 10.1093/jcag/gwab009
Source DB: PubMed Journal: J Can Assoc Gastroenterol ISSN: 2515-2084
Demographic characteristics of focus group participants
| Providers ( | |
|---|---|
| Gender, Female (%) | 10 (55.6%) |
| Age, median (IQR) | 45.5 (42, 50) |
| Province of practice | |
| Ontario | 9 (50.0%) |
| Québec | 8 (44.4%) |
| British Columbia | 1 (5.6%) |
| Practice type | |
| Academic | 15 (83.3%) |
| Community-based | 3 (16.7%) |
| Specialty | |
| Adult | 12 (66.7%) |
| Pediatric | 6 (33.3%) |
| Years in practice, median (IQR) | 15.0 (10.0, 20.7) |
| IBD patients treated per month, median (IQR) | 75 (40.0, 100.0) |
| Proportion of practice consisting of IBD patients, median (IQR) | 0.725 (0.525, 0.875) |
| Number of transitioning adolescents IBD patients per month | |
| Pediatric GI (patients transferred), median (IQR) | 3.75 (1.75, 5.0) |
| Adult GI (patients received), median (IQR) | 1.75 (1.375, 3.125) |
GI, Gastroenterologist; IBD, Inflammatory bowel disease; IQR, Interquartile range.
Template for the medical summary transfer letter
| Requests | |
|---|---|
| From adult gastroenterologists | • Priority of transfer: |
| • Urgent (within 3 months) | |
| • Semi-urgent (within 6 months) | |
| • Non-urgent (within 12 months, or within 6–12 months of 18th birthday) | |
| • Two methods of delivery to ensure receipt (e.g., fax, email, mail) | |
| • Provide information in point-form or table format, chronologic order | |
| From pediatric gastroenterologists | • Notification that patient has been accepted for transfer and target date for appointment |
| • Notification that patient has been seen by adult gastroenterologist | |
| • Consultation letter from adult gastroenterologist once patient has been seen (within a reasonable period of time) | |
| Copies of letter to be sent to: | • Adult gastroenterologist |
| • Family physician | |
| • Other specialists involved in care | |
| • Patient | |
| Patient/disease characteristics | |
| Demographics | • Date of birth (Age) |
| • Biologic sex and gender identity (if different from sex) | |
| • Patient’s contact information (verified by pediatric team) | |
| Diagnosis and phenotype | • Date of diagnosis (at minimum, year of diagnosis) |
| • Disease type (CD, UC or IBD-U) | |
| • Disease location | |
| • Phenotype (Paris or Montreal classification) | |
| Comorbidities/other chronic diagnoses | • Related to IBD |
| • Unrelated to IBD | |
| Allergies | • Medications |
| • Other | |
| Therapeutics | |
| Medications | |
| Current and Historic | • Name and dose |
| • Dates (starting and discontinuation) | |
| • History of nonadherence (brief) | |
| • Reasons for stopping if applicable | |
| (e.g., side effects, complications, compliance) | |
| Biologics | • Dose and interval (at initial induction) |
| • Dose and interval (currently) | |
| • Reasons for escalation/de-escalation | |
| • Recent serum titers (Alternative: report in Labs section below) | |
| Corticosteroid history | • Number of courses |
| • Last course (dates) | |
| • Responsiveness | |
| Surgeries | |
| Historic | • Date |
| • Surgery description (including length of bowel resected if available) | |
| • Pathology results | |
| • Reason for surgery | |
| • Complications (if applicable) | |
| (Alternative: report in Complications section below) | |
| Clinical history and current status | |
| History of presenting illness | • Initial presentation at diagnosis (brief description of initial presentation and clinical course) |
| Current status | • Status: Stable/controlled or unstable/uncontrolled (provide disease activity index if possible) |
| • Most recent weight and height (include history of growth failure, if applicable) | |
| • Significant physical findings, if applicable | |
| Investigations | |
| Imaging: endoscopies | • Description of endoscopy at diagnosis (including date, disease location, severity, pathology results) |
| • Description of last endoscopy (including date, disease location, severity, pathology results) | |
| • Description of video capsule endoscopy (including date, disease location, severity) | |
| • Brief listing of other endoscopies (date, results), or attach endoscopy and pathology reports as addendum | |
| • If applicable, was cancer surveillance colonoscopy conducted or discussed with the family? | |
| Imaging: radiology | • Initial radiology results (especially small bowel imaging) |
| • Most recent small bowel imaging | |
| • If applicable, bone density and CT scans or attach all radiology reports as addendum | |
| Labs: previous noteworthy investigations | • TPMT status |
| • Viral serologies (Hepatitis A, Hepatitis B, Hepatitis C, CMV, EBV, Varicella) | |
| • Tuberculosis testing results | |
| • IBD-related antibody serology results | |
| Labs: recent investigation | • Most recent laboratory investigations |
| • Most recent serum drug titers (with dose/interval of medication administration) | |
| • Fecal calprotectin | |
| History of complications | |
| Hospitalizations | • List all hospitalizations with dates, reason for hospitalization, and brief description of clinical course |
| Other complications | • If not listed under comorbidities above, highlight complications due to IBD or medications (especially hematologic, rheumatologic, dermatologic, ophthalmologic, bone health) |
| Other: | |
| Family history | • Where applicable, relevant family history (IBD, cancer) |
| Immunization history | • If available |
| • If not available, should report this. | |
| • List of immunizations that are missing or due to be given | |
| Psychosocial | • If applicable, history of mental illness, substance abuse, psychosocial risk factors |
| • Current and historic smoking status (including vaping) | |
| • Current and historic cannabis use | |
| • Current and historic alcohol use | |
| • Living situation, family conflict | |
|
| |
| Attachments | |
| Suggested attachments | • Endoscopies reports and pathology results |
| • Video capsule endoscopy reports | |
| • Surgical and related pathology reports | |
| • Relevant radiology reports (small bowel imaging, bone density) | |
| • Hospital discharge summaries for noteworthy hospitalizations | |
| • Consultation reports and most recent clinical report from other specialist physicians involved with patient care (rheumatology, dermatology, hematology, ophthalmology) |
CD, Crohn’s disease; CMV, Cytomegalovirus; EBV, Epstein Barr virus; IBD, Inflammatory bowel disease; IBD-U, IBD type unclassified; TPMT, Thiopurine methyltansferase; UC, Ulcerative colitis.